Status:
COMPLETED
Symptom Adapted Therapy in GERD Patients
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to determine whether a maintenance treatment over 12 weeks with esomeprazole 20 mg daily will sufficiently give control over GERD symptoms and how it compares either with a...
Eligibility Criteria
Inclusion
- Signed informed consent
- Patients who seek medical advice in primary care for symptoms thought to be GERD-related
Exclusion
- Clinical GERD diagnosis/treatment within last 3 month
- History of severe esophagitis (i.e. LA grade C or D)
- Previous anti-reflux surgery
- History of drug abuse
- Female patients who are pregnant or lactating or at risk of pregnancy
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
441 Patients enrolled
Trial Details
Trial ID
NCT00343161
Start Date
August 1 2006
End Date
August 1 2007
Last Update
January 24 2011
Active Locations (96)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aiterhofen, Germany
2
Research Site
Ansbach, Germany
3
Research Site
Apolda, Germany
4
Research Site
Bad Bramstedt, Germany